Ole Isacson is a professor of neurology at Harvard Medical School and a founding director of the Neuroregeneration Research Institute at McLean Hospital. He specializes in understanding and treating neurodegenerative disease, with particular emphasis on distinguishing critical mechanisms and treatments of neuronal vulnerability at the onset of disease.
Ole is a member of the Scientific Advisory Board of the Harvard NeuroDiscovery Center, principal faculty of the Harvard Stem Cell Institute, member of the FDA Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC), and editor-in-chief of the journal Molecular and Cellular Neuroscience. He received his MB and Dr Med Sci, PhD in Medical Neurobiology from the University of Lund in Sweden and an honorary MA from Harvard University.
Lewis Cantley is the Director of the Sandra and Edward Meyer Cancer Center and Professor of Cancer Biology in Medicine at Weill Cornell Medical College. He has made significant advances to the understanding of cancer metabolism, particularly in the discovery and study of the enzyme PI-3-kinase, which is now known to play an important role in cancer and diabetes mellitus. Lewis was formerly a professor in the Departments of Systems Biology and Medicine at Harvard Medical School, and the Director of Cancer Research at the Beth Israel Deaconess Medical Center, in Boston, Massachusetts. Lewis received his PhD in biophysical chemistry from Cornell University and conducted postdoctoral research at Harvard University.
Heidi McBride is a Canada Research Chair in Mitochondrial Cell Biology and Professor in the Department of Neurology and Neurosurgery at McGill University. She is an expert in understanding the biology and inner workings of the mitochondria, particularly related to how these highly dynamic structures merge, branch, and separate. She began her research career at the University of Ottawa Heart Institute before moving to McGill University in 2011. Through her lab’s research, Heidi seeks to discover new therapeutic approaches to treat various degenerative brain diseases caused by mitochondrial dysfunction.
Heidi received her PhD in biochemistry from McGill University and conducted postdoctoral research at the EMBL in Heidelberg, Germany.
Are you a patient, caregiver, clinician or professional and want to learn more about CervoMed’s approach? Please contact us.
Contact UsNew analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD) co-pathology — experienced greater clinical benefit with
Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial
Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB) DLB is the second most common progressive dementia,
